TL;DR
Get oils, diffusers and self-care delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A MedPage Today endocrinology roundup published Oct. 6, 2026, points to three developments: questions about tracking menopause with wearables, increased GLP-1 prescribing among surgery-eligible adolescents, and a meta-analysis linking iatrogenic menopause with elevated cardiovascular and mortality risks. The cited reports do not establish that wearables can diagnose menopause, explain why most eligible teens received neither treatment, or show that the meta-analysis proves causation.
A MedPage Today endocrinology roundup published Oct. 6, 2026, highlights three developments in reproductive and metabolic health: questions about what wearable devices can track during menopause, increased GLP-1 prescribing among adolescents eligible for bariatric surgery, and a meta-analysis associating iatrogenic menopause with higher cardiovascular and mortality risks. The cited material describes emerging research and reporting, not a clinical validation of wearables or proof that menopause-related interventions cause the observed health outcomes.
The roundup points readers to a New York Times report asking what menopause-related information devices such as Apple Watches can track. The MedPage item does not list the signals or measures discussed in that article, nor does it say that a wearable can diagnose menopause. That distinction matters: collecting health-related data is not the same as establishing a diagnosis or showing that a measurement is clinically reliable.
On adolescent treatment, the roundup cites a JAMA Pediatrics study reporting that GLP-1 medication prescribing rose from 2017 to 2025 among teens eligible for bariatric surgery. Despite that increase, nine out of 10 eligible adolescents received neither GLP-1 medication nor bariatric surgery, according to the summary. The supplied report gives no underlying patient count, prescribing rates, or explanation for why most did not receive either option.
A separate meta-analysis of 36 studies, published in JAMA Network Open, found that iatrogenic menopause was associated with significantly higher risks of stroke, coronary heart disease, composite cardiovascular events and all-cause mortality. Iatrogenic menopause refers to menopause caused by medical treatment or intervention. The roundup does not provide effect sizes, study populations or details about the interventions, limiting what can be concluded from the summary alone.
Three Questions for Patient Care
The items matter because they touch on how health is measured, who receives treatment and how risks are weighed. Wearables may offer people a way to monitor bodily patterns, but readers need to know what a device actually measures and whether those readings have been validated for menopause-related use. The cited roundup raises the question without supplying those answers.
The teen prescribing figures point to a gap between rising use of GLP-1 drugs and the proportion of eligible adolescents receiving either medication or surgery. The figures alone do not reveal whether the gap reflects access, clinical decisions, patient preferences, eligibility details or other factors. Those distinctions are needed before interpreting the number as evidence of unmet need or an appropriate treatment rate.
The iatrogenic menopause findings may be relevant to discussions about long-term health after medically induced menopause. However, an association across studies does not by itself establish cause and effect or indicate an individual patient’s risk. The findings are a reason to examine the evidence and clinical circumstances, not a stand-alone basis for changing treatment.
menopause tracking wearable devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evidence Behind the Roundup
The source is a short MedPage Today roundup of endocrinology news and commentary, rather than a single original investigation. Its items link to reporting or research from outlets and journals including the New York Times, JAMA Pediatrics and JAMA Network Open. The three topics therefore have different kinds of evidence: a question raised by news coverage, a prescribing trend reported in a study, and a meta-analysis combining findings from multiple studies.
The roundup also notes that the World Health Organization was scheduled to launch two guidelines on integrated obesity management in children and adolescents on Wednesday. It does not provide the guidelines’ recommendations. That item supplies broader policy context for the discussion of adolescent obesity treatment, but the source does not say the guidelines caused or explain the prescribing trends.
Other items in the roundup include a systematic review of pelvic pain among transmasculine people and a cohort study linking functional hypothalamic amenorrhea in mid-adulthood with coronary heart disease risk. Those reports show the range of topics covered, but they do not supply further evidence about the three developments summarized here.
What the Summaries Cannot Establish
The source material does not identify which menopause-related measures the wearable report discussed, how accurate they are, or whether clinicians use them in diagnosis. It also does not provide the teen study’s methods, absolute prescribing rates or reasons for non-treatment. The stated 2017–2025 period gives a time window, but no baseline multiplier or numerical rate is supplied, so the size of the increase cannot be calculated from the roundup.
For the meta-analysis, the summary does not give the size of the associations, how the studies defined iatrogenic menopause, or how researchers accounted for differences among patients and treatments. The word “associated” describes a relationship in the analysis; it does not establish that medically induced menopause caused each outcome. The underlying studies and full results are needed to assess the strength and limits of the evidence.
Full Studies and Guidelines Ahead
Readers seeking details will need to consult the original New York Times report, the JAMA Pediatrics study and the full JAMA Network Open meta-analysis. Those sources can clarify the wearable measures, study populations, numerical results and limitations that the brief roundup does not include. The WHO’s two child and adolescent obesity guidelines were described as launching Wednesday, but the source does not state their final recommendations or report on their release.
Until those details are available in the supplied material, the safest reading is limited: GLP-1 prescribing increased over the reported period among a defined group of eligible teens; most in that group received neither of the two treatments counted; and a meta-analysis found associations between iatrogenic menopause and several adverse outcomes. Whether these findings change clinical practice is not established by the roundup.
Key Questions
Can an Apple Watch diagnose menopause?
The supplied report does not say that an Apple Watch or another wearable can diagnose menopause. It points to a news article asking what menopause-related information wearables can track, but gives no validation data or diagnostic guidance.
What happened to GLP-1 prescribing among eligible teens?
The cited JAMA Pediatrics study summary says prescribing increased from 2017 to 2025 among adolescents eligible for bariatric surgery. It also says nine out of 10 eligible teens received neither GLP-1 medication nor bariatric surgery.
What does the iatrogenic menopause meta-analysis report?
The summary of a 36-study meta-analysis says iatrogenic menopause was associated with higher risks of stroke, coronary heart disease, composite cardiovascular events and all-cause mortality. It does not provide effect sizes or establish that the association is causal.
Why did most eligible adolescents receive neither treatment?
The roundup does not explain why. It provides no information about access, clinical decisions, patient preferences or other possible reasons, so the cause of the treatment gap remains unclear.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
